CAIRO, Stefano Enrico
 Distribuzione geografica
Continente #
NA - Nord America 2.128
EU - Europa 383
AS - Asia 261
AF - Africa 8
SA - Sud America 2
Continente sconosciuto - Info sul continente non disponibili 1
Totale 2.783
Nazione #
US - Stati Uniti d'America 2.127
CN - Cina 180
UA - Ucraina 88
DE - Germania 83
SE - Svezia 72
TR - Turchia 64
IT - Italia 48
GB - Regno Unito 43
FI - Finlandia 29
FR - Francia 10
IR - Iran 7
MA - Marocco 7
RU - Federazione Russa 5
IN - India 4
HK - Hong Kong 2
KR - Corea 2
BE - Belgio 1
BR - Brasile 1
CH - Svizzera 1
CL - Cile 1
EG - Egitto 1
ES - Italia 1
EU - Europa 1
MD - Moldavia 1
MX - Messico 1
SK - Slovacchia (Repubblica Slovacca) 1
TW - Taiwan 1
VN - Vietnam 1
Totale 2.783
Città #
Fairfield 322
Woodbridge 286
Chandler 157
Houston 151
Ashburn 149
Jacksonville 131
Ann Arbor 126
Seattle 124
Wilmington 120
Cambridge 101
Beijing 55
Izmir 47
New York 45
Nanjing 37
Dearborn 35
Princeton 29
Boardman 22
Ferrara 22
Bremen 20
San Diego 18
Falls Church 16
Shanghai 14
Nanchang 13
Augusta 10
Hebei 10
Shenyang 8
Des Moines 7
Jiaxing 7
Ardabil 6
Guangzhou 6
Hangzhou 6
Addison 5
Changsha 5
Chicago 5
Norwalk 5
Redwood City 5
Casalecchio Di Reno 4
Leawood 4
London 4
Los Angeles 4
Mountain View 4
Orange 4
San Mateo 4
Tianjin 4
Auburn Hills 3
Fes 3
Milan 3
Redmond 3
Tappahannock 3
Atlanta 2
Frankfurt am Main 2
Fuzhou 2
Helsinki 2
Hong Kong 2
Kilburn 2
Kunming 2
Mumbai 2
San Francisco 2
Shangdi 2
Acton 1
Arlington Heights 1
Bratislava 1
Brussels 1
Cairo 1
Casalgrande 1
Changchun 1
Chisinau 1
Chiswick 1
Chongqing 1
Ciminna 1
Dallas 1
Fontenay-sous-bois 1
Giugliano In Campania 1
Guadalajara 1
Hanoi 1
Hefei 1
Jinan 1
Lanciano 1
Lequile 1
Niterói 1
Nova Milanese 1
Paris 1
Piossasco 1
Renton 1
Seoul 1
Seregno 1
Taipei 1
Taiyuan 1
Venezia 1
Walnut 1
Wandsworth 1
Washington 1
Wenzhou 1
Totale 2.226
Nome #
Abstract P5-06-04: The PARP inhibitor niraparib demonstrated activity in patient-derived triple-negative breast cancer xenograft models with high homologous recombination deficiency (HRD) score 143
Activation of Wnt and Myc signaling in hepatoblastoma 138
Early activation of IFN/STAT signaling in tumor cells of patient-derived triple negative breast cancer xenografts predicts tumor sensitivity to chemotherapy 135
The genomic landscape of hepatoblastoma and their progenies with HCC-like features 121
Reprogramming of miRNA networks in cancer and leukemia 109
The MET Inhibitor AZD6094 (Savolitinib, HMPL-504) induces regression in papillary renal cell carcinoma patient-derived xenograft models 109
Functional genomics of the B-box gene family reveals a possible role in subcellular compartmentalization 109
PML interacts with Myc, and Myc target gene expression is altered in PML-null fibroblasts 109
Deficiency of multidrug resistance 2 contributes to cell transformation through oxidative stress 108
The four and a half LIM-only protein 2 regulates liver homeostasis and contributes to carcinogenesis 106
Functional characterization of the OFD1 protein reveals a nuclear localization and physical interaction with subunits of a chromatin remodeling complex 106
The tripartite motif family identifies cell compartments 104
Mlx, a new Max-like bHLHZip family member: the center stage of a novel transcription factors regulatory pathway? 102
The hepatitis B virus X protein functionally interacts with CREB-binding protein/p300 in the regulation of CREB-mediated transcription 101
TAK1 suppresses a NEMO-dependent but NF-kappaB-independent pathway to liver cancer 101
Myc target miRs and liver cancer: small molecules to get Myc sick 99
Stem cell-like micro-RNA signature driven by Myc in aggressive liver cancer 98
Subset of Suz12/PRC2 target genes is activated during hepatitis B virus replication and liver carcinogenesis associated with HBV X protein 97
How transient becomes stable: an epigenetic switch linking liver inflammation and tumorigenesis 97
Preferential localization of tyrosine-phosphorylated paxillin in focal adhesions 94
LIM-only protein FHL2 activates NF-κB signaling in the control of liver regeneration and hepatocarcinogenesis 88
null 83
The sialyl-glycolipid stage-specific embryonic antigen 4 marks a subpopulation of chemotherapy-resistant breast cancer cells with mesenchymal features 80
CA3-Classification de l’hépatoblastome par l'étude en microarray du profil d’expression génétique 76
null 76
Heterogeneous expression of EPCAM in human circulating tumour cells from patient-derived xenografts 67
Patient-derived xenografts from pediatric liver cancer predict tumor recurrence and advise clinical management 61
Hepatic stem-like phenotype and interplay of Wnt/$\beta$-catenin and Myc signaling in aggressive childhood liver cancer 58
Targeting the Vav1/miR‐29b axis as a potential approach for treating selected molecular subtypes of triple‐negative breast cancer 22
Activation of IFN/STAT1 signalling predicts response to chemotherapy in oestrogen receptor-negative breast cancer 16
Abstract B11: A panel of patient-derived xenografts for preclinical efficacy studies in various breast cancer molecular subtypes 9
SSEA4 AND ST3GAL2 AS CHEMOTHERAPEUTIC DRUG RESPONSE BIOMARKERS 8
Establishment and characterization of circulating tumor cell-derived xenografts in non-small cell lung cancer 7
Functional evaluation of interferon/STAT1 pathway activation in response to genotoxic treatment 6
Genomic analysis of the TRIM family reveals two groups of genes with distinct evolutionary properties 6
Expression profiling and CGH array as prognostic tools in hepatoblastoma 6
A panel of pediatric liver cancer patient-derived xenografts to improve stratification of children with hepatoblastoma 4
The PARP inhibitor niraparib demonstrates robust activity in a subset of patient-derived triple-negative breast cancer xenograft models 3
Vav1 Selectively Down-Regulates Akt2 through miR-29b in Certain Breast Tumors with Triple Negative Phenotype 2
Polo-like kinase 1 inhibition suppresses hepatitis B virus X protein-induced transformation in an in vitro model of liver cancer progression 1
Preclinical evaluation of the PARP inhibitor niraparib and cytotoxic chemotherapy alone or in combination in a panel of 25 triple-negative breast cancer PDX models: Relevance of BRCA mutations, HRD status and other biomarkers 1
Understanding breast cancer resistance to chemotherapy: Characterization of cancer cell sub-populations in residual and relapsed tumors 1
Wnt signaling and hepatocarcinogenesis: The hepatoblastoma model 1
Tbx3 is a downstream target of the Wnt/$\beta$-catenin pathway and a critical mediator of $\beta$-catenin survival functions in liver cancer 1
Totale 2.869
Categoria #
all - tutte 11.593
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 11.593


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/2019247 0 0 0 0 0 0 0 0 0 0 105 142
2019/2020727 104 26 31 104 48 74 118 61 69 49 27 16
2020/2021452 32 27 26 82 13 46 11 49 11 44 79 32
2021/2022313 20 21 16 7 31 30 12 26 11 38 33 68
2022/2023361 30 33 27 36 70 45 11 29 43 5 20 12
2023/2024152 14 26 7 6 7 52 5 19 6 10 0 0
Totale 2.869